Présentation de l'entreprise
ZeroStack Corp. (ZSTK) operates within the Financial Services sector, specifically focusing on the Asset Management industry, although its primary operational activities involve pharmaceutical distribution in Germany. Through its subsidiary, Phatebo GmbH, the corporation engages in the distribution of pharmaceutical goods and medical products designed to treat various health indications, serving both commercial and wholesale markets while also exploring digital assets segments. The company maintains a relatively small organizational structure with a workforce comprising 21 employees, which is consistent with specialized distribution or asset management entities that rely on lean operational models. With a market capitalization of $11.98M and trailing twelve-month revenue of $35.68M, ZeroStack Corp. presents a profile of a micro-cap entity with significant revenue generation relative to its size. These valuation figures indicate that the company possesses a revenue base substantially larger than what would be expected for an organization with only 21 employees, suggesting either highly efficient operations or a specific niche market position that generates disproportionate income flow compared to its listed market value.
Santé financière
The financial performance of ZeroStack Corp. reveals a distinct divergence between top-line activity and bottom-line profitability, as evidenced by its reported revenue of $35.68M contrasted sharply against a net income loss of $115,410,000. This substantial gap between revenue and net income highlights a severe cost structure issue where operating expenses likely exceed total revenue, resulting in a negative profit environment that erodes the entire sales figure. The company's EBITDA stands at $-11,027,000, further confirming that core business operations are currently generating negative cash earnings before interest, taxes, depreciation, and amortization. Free cash flow is reported at $-5,176,000, indicating that the company is burning cash rather than generating liquidity, which limits its financial flexibility for capital expenditures or organic expansion without external financing. Margin analysis underscores this distress, with a gross margin of 4.6% suggesting thin pricing power or high cost of goods sold, an operating margin of -54.8% reflecting inefficient operational overhead, and a profit margin of 0.0% which technically registers as negative in this context of heavy losses. The balance sheet displays a leverage profile where total debt of $53.93M significantly outweighs cash reserves of $5.60M, resulting in a debt-to-equity ratio of 76.44 that characterizes a highly leveraged position rather than a conservative one. Liquidity is constrained by a current ratio of 1.01, meaning current assets barely cover current liabilities, leaving little room for error in short-term cash management. Furthermore, return metrics paint a picture of capital destruction, with a return on equity of -307.5% and a return on assets of -9.3%, revealing that management is not generating positive value from shareholder capital or asset bases but rather diluting equity value through losses.
Évaluation de la valorisation
Valuation metrics for ZeroStack Corp. are constrained by the lack of normalized earnings, resulting in a trailing P/E ratio and forward P/E ratio both listed as N/A due to the negative net income. The absence of a positive P/E ratio implies that traditional earnings-based valuation models are inapplicable, forcing reliance on alternative metrics to assess the company's worth relative to its book value. The price-to-book ratio stands at 0.07, indicating that the market values the company's equity at a fraction of its accounting book value, which often occurs when assets are overvalued on the books or when the business is generating losses that depress the intrinsic value. Price-to-sales is calculated at 0.34, suggesting the stock trades at a low multiple of revenue, while the EV/EBITDA stands at -5.47, reflecting the negative enterprise value dynamics associated with high debt and losses. The stock price has exhibited significant volatility, trading between a 52-week low of $4.78 and a 52-week high of $47.00, placing the current valuation well below the recent peak and reflecting market skepticism regarding the company's ability to return to profitability. With a beta of 2.01, the stock demonstrates price volatility that is more than double that of the broader market, indicating high sensitivity to market fluctuations and sector-specific risks.
Growth & Income
Revenue growth for the trailing twelve months is recorded at 22.3%, signaling an expansion in top-line sales, whereas earnings growth is listed as N/A due to the persistent negative net income and lack of comparable profitable periods. The disparity between positive revenue growth and the inability to generate earnings growth suggests that the company is expanding its sales base but failing to convert this into net profit, likely due to the high fixed costs or debt servicing obligations mentioned in the financial health section. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute income to shareholders, implying that any retained earnings are insufficient for distribution and are instead absorbed by operational deficits. This reinvestment strategy, or lack thereof due to losses, means the company is currently prioritizing survival over shareholder returns or external growth initiatives that would require free cash flow. The overall growth and income profile is characterized by expanding revenue streams that have not yet been matched by profitability, resulting in a financial structure that relies on cash reserves and external capital to fund operations while the path to positive earnings remains uncertain.